BLTE
Price
$61.25
Change
+$0.33 (+0.54%)
Updated
Jul 21, 03:49 PM (EDT)
Capitalization
1.98B
16 days until earnings call
NAMS
Price
$22.40
Change
+$0.20 (+0.90%)
Updated
Jul 21, 04:27 PM (EDT)
Capitalization
2.49B
22 days until earnings call
Interact to see
Advertisement

BLTE vs NAMS

Header iconBLTE vs NAMS Comparison
Open Charts BLTE vs NAMSBanner chart's image
Belite Bio
Price$61.25
Change+$0.33 (+0.54%)
Volume$100
Capitalization1.98B
NewAmsterdam Pharma
Price$22.40
Change+$0.20 (+0.90%)
Volume$271
Capitalization2.49B
BLTE vs NAMS Comparison Chart in %
Loading...
BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BLTE vs. NAMS commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLTE is a Hold and NAMS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (BLTE: $60.92 vs. NAMS: $22.20)
Brand notoriety: BLTE and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BLTE: 62% vs. NAMS: 112%
Market capitalization -- BLTE: $1.98B vs. NAMS: $2.49B
BLTE [@Biotechnology] is valued at $1.98B. NAMS’s [@Biotechnology] market capitalization is $2.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BLTE’s FA Score shows that 0 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • BLTE’s FA Score: 0 green, 5 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, NAMS is a better buy in the long-term than BLTE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BLTE’s TA Score shows that 4 TA indicator(s) are bullish while NAMS’s TA Score has 5 bullish TA indicator(s).

  • BLTE’s TA Score: 4 bullish, 5 bearish.
  • NAMS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than BLTE.

Price Growth

BLTE (@Biotechnology) experienced а -3.64% price change this week, while NAMS (@Biotechnology) price change was +3.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.59%. For the same industry, the average monthly price growth was +16.03%, and the average quarterly price growth was +35.36%.

Reported Earning Dates

BLTE is expected to report earnings on Aug 06, 2025.

NAMS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+2.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($2.49B) has a higher market cap than BLTE($1.98B). BLTE YTD gains are higher at: -3.455 vs. NAMS (-13.619). BLTE has higher annual earnings (EBITDA): -43.31M vs. NAMS (-254.89M). NAMS has more cash in the bank: 808M vs. BLTE (145M). NAMS has less debt than BLTE: NAMS (389K) vs BLTE (537K). NAMS has higher revenues than BLTE: NAMS (47.1M) vs BLTE (0).
BLTENAMSBLTE / NAMS
Capitalization1.98B2.49B80%
EBITDA-43.31M-254.89M17%
Gain YTD-3.455-13.61925%
P/E RatioN/AN/A-
Revenue047.1M-
Total Cash145M808M18%
Total Debt537K389K138%
TECHNICAL ANALYSIS
Technical Analysis
BLTENAMS
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
61%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
39%
Momentum
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
46%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
47%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
80%
Bullish Trend 4 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
55%
Advances
ODDS (%)
Bullish Trend 8 days ago
76%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 6 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
53%
Aroon
ODDS (%)
Bearish Trend 4 days ago
78%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIGPX19.380.07
+0.36%
Morgan Stanley Inst Global Insgt A
DGBCX8.480.02
+0.24%
BNY Mellon Developed Markets RE Scs - C
TRZLX43.86-0.04
-0.09%
T. Rowe Price US Large-Cap Core Z
UIGRX41.84-0.05
-0.12%
Victory Growth Institutional
CIESX26.67-0.09
-0.34%
Calvert International Equity R6

BLTE and

Correlation & Price change

A.I.dvisor tells us that BLTE and ACOG have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BLTE and ACOG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLTE
1D Price
Change %
BLTE100%
-0.11%
ACOG - BLTE
27%
Poorly correlated
-2.73%
FGHQF - BLTE
25%
Poorly correlated
N/A
NAMS - BLTE
23%
Poorly correlated
+1.00%
URGN - BLTE
23%
Poorly correlated
-0.91%
HRMY - BLTE
23%
Poorly correlated
-0.03%
More

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+1.00%
QURE - NAMS
57%
Loosely correlated
-1.38%
CRDF - NAMS
43%
Loosely correlated
-3.82%
IRON - NAMS
40%
Loosely correlated
-0.03%
NRIX - NAMS
38%
Loosely correlated
-7.28%
BEAM - NAMS
38%
Loosely correlated
+1.47%
More